研究概要
肝细胞癌(HCC)因其高度异质性、诊断时多为晚期以及化疗耐药性,构成了巨大的治疗挑战。
中文摘要
肝细胞癌 (HCC) 由于其高度异质性、频繁的晚期诊断和化疗耐药,构成了巨大的治疗挑战。自然杀伤 (NK) 细胞对免疫监视至关重要,但在 HCC 进展过程中其数量和功能均显著受损,从而促进肿瘤免疫逃逸。本综述系统概述了当前针对 HCC 的基于 NK 细胞的免疫治疗策略,包括过继性 NK 细胞转移、NK 细胞的基因工程改造、靶向 NK 细胞抑制性受体的治疗、重编程免疫抑制性 HCC 微环境、细胞因子介导的 NK 细胞功能增强,以及中医药增强的 NK 细胞细胞毒性。作为一种有前景的免疫治疗范式,基于 NK 细胞的治疗正迅速从传统细胞输注向更精准的模式推进,包括 CAR-NK 细胞和多功能抗体衔接器。然而,这些方法的疗效常因免疫抑制性肿瘤微环境和肿瘤异质性而受限。鉴于 NK 细胞功能障碍具有多因素性质,我们强调,合理设计的联合策略——整合基因工程、TME 重编程和检查点阻断——代表了在 HCC 中实现持久临床反应的最可行路径。
展开英文摘要原文
Hepatocellular carcinoma (HCC) poses a formidable therapeutic challenge due to its high heterogeneity, frequent late-stage diagnosis, and chemoresistance. Natural killer (NK) cells are essential for immune surveillance, yet their quantity and function become significantly compromised during HCC progression, thereby promoting tumour immune escape. This review systematically outlines current NK cell-based immunotherapeutic strategies for HCC, including adoptive NK cell transfer, genetic engineering of NK cells, NK cell inhibitory receptor-targeted therapies, reprogramming of the immunosuppressive HCC microenvironment, cytokine-mediated enhancement of NK cell function, and traditional Chinese medicine-augmented NK cell cytotoxicity. Representing a promising immunotherapeutic paradigm, NK cell-based therapy is rapidly advancing from conventional cell infusion toward more precise modalities, including CAR-NK cells and multifunctional antibody engagers. However, the efficacy of these approaches is frequently curtailed by the immunosuppressive tumour microenvironment and tumour heterogeneity. Given the multifactorial nature of NK cell dysfunction, we highlight that rationally designed combination strategies-integrating genetic engineering, TME reprogramming, and checkpoint blockade-represent the most viable path toward durable clinical responses in HCC.
论文信息
- 作者
- Che L、Xie X、Yang X、Zhu S、Zhou Y
- 单位
- Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.China
- 文献类型
- 综述
- 期刊
- Immunology2026 Aug